Bimat + Applicators

Basic Bimat + Applicators information

• INN (international nonproprietary name): Bimatoprost.
• Brand names available in the United Kingdom: Lumigan; generic bimatoprost eye drops.
• ATC code: S01EE03.
• Forms & dosages: Ophthalmic solution formulations at 0.01% and 0.03% concentrations; typical pack sizes include 3 mL and 5 mL bottles.
• Manufacturers: Allergan/AbbVie (originator); generic manufacturers such as Viatris and Medochemie.
• Registration status in the United Kingdom: Prescription-only medicine (POM).
• OTC / Rx classification: Prescription only (Rx) in the UK.

Legal status and availability in the UK

In our online pharmacy, Bimat + Applicators is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Clinical effectiveness in the United Kingdom

Most patients with eyelash hypotrichosis see visible benefit from bimatoprost by four to eight weeks and clear improvement by week 16.

For glaucoma, bimatoprost—prescribed under brand names such as Lumigan or as generics—achieves IOP reductions comparable to latanoprost.

Switching between prostaglandins is common where adherence or tolerability is an issue.

• Typical effects: lash length gains, perceived fuller lashes, transient redness, staining of pillowcases or skin, and concerns about permanent iris pigmentation.

Typical dosing: eyelash use 0.03% nightly to the upper eyelid margin; glaucoma dosing one drop once daily.

Indications and expanded uses

Should you expect bimatoprost to be prescribed for lashes on the NHS?

In the UK, bimatoprost is licensed for glaucoma and ocular hypertension; it is not licensed for eyelash growth.

In UK practice, dermatology and aesthetic clinics commonly offer bimatoprost off‑label for lashes or brows after informed consent and documentation.

• Licensed use: Treatment of glaucoma and ocular hypertension (prescription only).
• Off‑label cosmetic use: eyelash or eyebrow enhancement where supplied privately.

Consent checklist:

1. Documented discussion of permanent iris and eyelid pigmentation risk.
2. Ocular history screen for uveitis, aphakia, pseudophakia with torn capsule and macular disease.
3. Clear written consent for off‑label cosmetic application and follow‑up plan.

The NHS rarely funds bimatoprost for cosmetic reasons; glaucoma remains the primary NHS indication.

Composition and brand landscape

Which brands and formulations should patients ask about at the pharmacy?

INN for all products is bimatoprost and ATC classification is S01EE03.

Manufacturers include Allergan (AbbVie), Mylan, Sandoz, Viatris, Medochemie, Sun Pharma and Ajanta.

• Excipients to watch: benzalkonium chloride (BAK) as a preservative may aggravate dry eye or preservative sensitivity.
• Packaging notes: single‑use sterile applicators are included in many eyelash packs.

Contraindications and special precautions

What eye conditions should stop someone from starting bimatoprost?

• Absolute contraindications: Known hypersensitivity to bimatoprost or any excipient such as benzalkonium chloride.
• Active ocular infection/inflammation: Do not initiate therapy during active infection or uncontrolled inflammatory eye disease.

Pregnancy and breastfeeding lack sufficient safety data for cosmetic indications and should be avoided or discussed with a clinician; glaucoma treatment decisions require specialist input.

Iris pigmentation may be permanent even after stopping treatment, so counsel patients thoroughly before cosmetic use.

Dosage guidelines

How should patients apply bimatoprost to get results and avoid problems?

Standard adult dosing is clear in licensed literature for the two main uses.

• Eyelash hypotrichosis: 1 drop of 0.03% solution applied to the upper eyelid margin once nightly, using a sterile single‑use applicator per eye; wipe away excess; avoid direct eye instillation.
• Glaucoma/ocular hypertension: 1 drop into affected eye(s) once daily, either morning or evening but not both.

Onset and maintenance: expect some effect by week 4 and maximal improvement by week 16; continued use is required to maintain results.

Missed dose: apply at the next usual time and do not double up; overdose should prompt rinsing with water and clinician review if symptoms persist.

Interactions overview

Will bimatoprost interact with other eye drops or medicines I use?

Systemic interactions are unlikely with topical ocular bimatoprost at recommended doses.

• Concurrent use with other IOP‑lowering agents: additive effects on intraocular pressure are possible and monitoring should be adjusted accordingly.
• Simultaneous use with other ophthalmic prostaglandins (latanoprost, travoprost, tafluprost): clinicians generally reassess therapy rather than co‑prescribe these agents together.
• Preservative interaction: multiple preserved eye drops can increase local irritation due to benzalkonium chloride exposure.

Macular oedema has been reported rarely, mainly when bimatoprost is used alongside medicines or conditions that predispose to it or where ocular inflammation exists.

Always review recent ophthalmic surgery, full ocular medication lists and known preservative sensitivities before adding bimatoprost.

Comparable medicines and preferences

When might a clinician pick bimatoprost over another prostaglandin?

NHS clinicians commonly use latanoprost, travoprost or tafluprost as first‑line glaucoma therapy, choosing bimatoprost when those agents are less effective or not tolerated.

• Pros: proven efficacy for eyelash growth and effective once‑daily IOP reduction for glaucoma.
• Cons: risk of permanent pigmentation, local irritation and requirement for prescription.

Choice between Lumigan and generics depends on licensed indication, preservative content and patient risk factors such as prior surgery or preservative sensitivity.

Frequently asked questions

What are the quick answers people ask most about bimatoprost?

• Is bimatoprost available on the NHS for cosmetic lashes? No; NHS funding is for glaucoma treatment and cosmetic use is typically a private arrangement.
• Do I need a prescription for bimatoprost? Yes; in the UK bimatoprost is a prescription-only medicine.
• How long until lashes improve and do I need to keep using it? Expect some effect by week 4 and maximal effect by week 16; stopping therapy commonly reverses gains over a number of months.
• What are the biggest safety concerns? The main concerns are local irritation and potentially permanent iris or eyelid pigmentation; use single‑use applicators and report adverse events.

If you are unsure:

1. If you have eye disease or visual symptoms, seek GP or ophthalmologist review.
2. If you want cosmetic use without eye disease, discuss risks with a pharmacist or aesthetic clinician and obtain written consent.
3. Report suspected adverse reactions via the Yellow Card scheme and keep follow‑up arrangements in place.

Guidelines for proper use

What should a pharmacist cover when counselling someone starting bimatoprost?

• Confirm indication and whether use is licensed or off‑label for cosmetic purposes.
• Explain correct application: upper eyelid margin only for lash use, one sterile applicator per eye nightly, discard applicator after single use.
• Advise storage between 2–25°C and to avoid using if solution discolours or clouds.
• Instruct contact lens wearers to remove lenses before application and wait 15 minutes before reinsertion.
• Highlight adverse signs that need ophthalmology review: persistent redness, pain, vision change, or new pigmentation.

Provide printed or electronic leaflets that capture consent for off‑label cosmetic use and advise how to report adverse events via the MHRA Yellow Card scheme.

Yellow Card reporting: document the event, report via the MHRA Yellow Card website or the NHS app, and provide product batch details and your clinician contact when possible.

Delivery across the United Kingdom